U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07907861) titled 'Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy' on Oct. 26.
Brief Summary: This is a single-center, single-arm, open-label, Phase 2 clinical trial (the SCOPE study) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (SKB264) combined with toripalimab as a second-line, chemo-free treatment for patients with unresectable locally advanced or metastatic penile squamous cell carcinoma whose disease progressed on or who are intolerant to platinum-based chemotherapy.
Penile squamous cell carcinoma (PSCC) is a rare and aggressive cancer with limited treatment option...